This may be good news … or it may not …

Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).

A media release from the company (as one might expect) has placed the best possible “spin” on the announcement that data from the PROSPECT trial should now be expected in the fourth quarter of 2017 (i.e., some time between October and December).

The biotech news service FierceBiotech has a rather less positive perspective (which may also be more accurate) … but who knows?

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: